Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00

TriSalus Life Sciences (NASDAQ:TLSI) had its target price lowered by Canaccord Genuity Group from $12.00 to $11.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Mkm initiated coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price objective for the company. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Oppenheimer began coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Price Performance

TLSI stock traded down $0.08 during midday trading on Friday, reaching $3.93. 27,024 shares of the stock were exchanged, compared to its average volume of 38,374. The company has a fifty day moving average price of $4.33 and a 200 day moving average price of $5.80. The stock has a market capitalization of $119.83 million, a PE ratio of -1.57 and a beta of 0.49. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $7.36 million for the quarter. As a group, analysts anticipate that TriSalus Life Sciences will post -1.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Mary T. Szela bought 7,520 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $5.20 per share, with a total value of $39,104.00. Following the completion of the acquisition, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This trade represents a 2.03 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 32.80% of the stock is currently owned by insiders.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the second quarter valued at about $1,184,000. Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $240,000. Duquesne Family Office LLC boosted its stake in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. Finally, Vestcor Inc acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $108,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.